Developer docs
API playgroundTry for free, no card

Search company profiles

CamDiab

Full company profile

uuid000t138

Namestring
CamDiab
Legal namestring
CamDiab Ltd
Websiteurl
camdiab.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

CamDiab Ltd is a Cambridge- and London-based private digital health company that develops and commercialises the CamAPS FX mobile application, an adaptive hybrid closed-loop insulin delivery system for people aged one year and older with type 1 diabetes. The app connects to compatible continuous glucose monitors (Dexcom G6/G7, Abbott FreeStyle Libre 3/3 Plus) and insulin pumps (YpsoPump, DANA Diabecare RS, DANA-i), running the proprietary Cambridge self-learning algorithm — refined over 15+ years of research at the University of Cambridge and validated in randomised trials published in The Lancet, NEJM, and Diabetes Care — to compute and direct insulin doses every 8 to 12 minutes. In January 2026 the company received EU MDR notified body approval for CamAPS Liberty, the world's first commercially available fully closed-loop feature, which removes the need for carbohydrate counting and pre-meal bolusing.

CamDiab generates revenue through two complementary streams: direct app subscriptions sold via its website and the Google Play/Apple App Store (£80 per month, £450 per six months, or £840 per year, with a 30-day free trial), and B2B algorithm licensing and OEM integration with device partners — most prominently Ypsomed's mylife Diabetes Care, where CamAPS FX is embedded as the algorithm engine inside the myLoop AID system. Abbott and Dexcom partnerships extend CGM compatibility, while Cambridge Diabetes Education Programme (CDEP) certification provides free healthcare professional training as an indirect adoption driver. The company holds regulatory approvals across six major markets (UK, EU, USA, Canada, Australia, New Zealand), operates with 1-10 employees in a founder-led structure under Professor Roman Hovorka, and pursues growth through market-by-market geographic expansion, additional device integrations, and the staged rollout of its fully closed-loop CamAPS Liberty feature.

Short descriptiontext

CamDiab develops CamAPS FX, an adaptive hybrid closed-loop mobile app that automates insulin delivery for people with type 1 diabetes by linking continuous glucose monitors and insulin pumps to its proprietary Cambridge algorithm, with EU MDR-approved CamAPS Liberty extending it to fully closed-loop operation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
automated insulin delivery, diabetes management software, hybrid closed-loop app, continuous glucose monitoring, type 1 diabetes technology
Industry2 codes
PRIMARYHLAHAHAF
Automated Insulin Delivery (AID) / Closed-Loop Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Software Publishers513210
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Automated Insulin Delivery Software (Diabetes Management)
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1CamAPS FX App Subscription
TypeSubscription Recurring
Description

CamAPS FX is sold as a downloadable mobile app with monthly, 6-monthly, and annual subscription options. Subscriptions are purchased through the company website, Google Play, and Apple App Store, or via voucher codes. The app requires users to complete certified online training before activation. Pricing is publicly listed at £80/month, £450 for 6 months, or £840/year (plus VAT unless exempt). A 30-day free trial is available using discount code CamAPS30. Usage fees are payable in advance and non-refundable except in specific circumstances outlined in the T&Cs.

camdiab.com
2Healthcare Professional Training Services
TypeProfessional Services
Description

CamDiab provides FREE certified online HCP training via the Cambridge Diabetes Education Programme (CDEP). While the training itself is free, it serves as a gatekeeper and adoption driver for clinical prescription and recommendation of CamAPS FX, indirectly driving subscription revenue.

camdiab.com
3Algorithm Licensing / OEM Integration
TypeLicensing Royalties
Description

CamDiab's CamAPS algorithm is embedded within Ypsomed's mylife Loop/AID ecosystem and integrated with Abbott's FreeStyle Libre 3 and Dexcom G7. These partnerships suggest a licensing or OEM arrangement where CamDiab's technology is incorporated into partners' AID systems, generating revenue from technology integration fees or per-unit royalties.

abbott.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details3 tiers
1Monthly subscription — £80 per month
ModelSubscriptionBilling cadenceMonthly
Notes

£80 per month (+ VAT unless exempt). Payable in full following training/activation.

camdiab.com
26-month subscription — £450 (£30 saving)
ModelSubscriptionBilling cadenceMulti-year contract
Notes

£450 per 6 months (£75/month equivalent), saving £30 versus two 3-month blocks at £80/month.

camdiab.com
3Annual subscription — £840 (£120 saving)
ModelSubscriptionBilling cadenceAnnual
Notes

£840 per year (£70/month equivalent), saving £120 versus twelve months at £80/month.

camdiab.com
GTM typeB2C
B2C
Offering typeSoftware
Software
Brand1 of 3 records shown
1CamAPS FX
Description

Advanced adaptive hybrid closed-loop mobile app for people with type 1 diabetes that automatically adjusts insulin delivery based on sensor glucose readings.

camdiab.com
+2 more records
Core offering1 text field

CamDiab develops and commercialises the CamAPS FX mobile application, an adaptive hybrid closed-loop system that automatically adjusts insulin delivery from a compatible insulin pump based on continuous glucose monitor (CGM) readings every 8–12 minutes for people with type 1 diabetes aged one year and over. The app is sold on a subscription basis directly to consumers via app stores and the company website, and is also licensed as the algorithm engine within partner AID ecosystems such as Ypsomed's myLoop system, with Abbott FreeStyle Libre 3 and Dexcom G7 sensor integrations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Significant increase in time in range, reduction in HbA1c, reduction in time spent in hypoglycaemia and hyperglycaemia, and improved well-being (randomised clinical trials)
+4 more records
Product overview1 text field

CamDiab offers a mobile health platform centered on its CamAPS FX app, an advanced adaptive hybrid closed-loop system for automated insulin delivery in type 1 diabetes. The core CamAPS FX app connects to compatible continuous glucose monitors (Dexcom G6/G7, FreeStyle Libre 3/3 Plus) and insulin pumps (YpsoPump, DANA Diabecare RS, DANA-i) to autonomously compute and direct insulin delivery. The company has expanded its portfolio with CamAPS Liberty, the world's first commercially available fully closed-loop feature, which removes the need for carb counting and meal bolusing. CamAPS HX represents an extension for non-type 1 diabetes populations. The platform is complemented by data sharing integrations with mylife Cloud and Glooko, and the Companion feature enabling remote caregiver monitoring.

Product and service3 records
1CamAPS FX
CategoryAutomated insulin delivery / diabetes management software
Description

Advanced adaptive hybrid closed-loop mobile application that automatically adjusts insulin delivery on a compatible insulin pump based on continuous glucose monitor (CGM) sensor readings every 8–12 minutes. Designed for people with type 1 diabetes aged one year and older who use a compatible CGM and insulin pump. Sold via subscription through app stores and the CamDiab website, and licensed into partner AID systems.

2CamAPS Liberty
CategoryAutomated insulin delivery / diabetes management software
Description

Fully closed-loop feature within the CamAPS FX app that, when activated, removes the need for users to count carbohydrates or deliver pre-meal insulin boluses. The algorithm autonomously handles meal-related insulin dosing while maintaining established safety boundaries, targeting people with type 1 diabetes aged 13 and over.

3CamAPS HX
CategoryAutomated insulin delivery / diabetes management software
Description

App offering fully closed-loop insulin delivery for non-type 1 diabetes populations, extending the CamAPS algorithm beyond its type 1 diabetes indication.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-03
Description

CamAPS FX is embedded as the algorithm engine within Ypsomed's mylife Loop/AID ecosystem, integrating the YpsoPump insulin pump with CamAPS FX and compatible sensors. Ypsomed distributes the combined system globally, with the Dexcom G7 integration (June 2026) jointly announced by all three companies. This is CamDiab's primary channel partnership and the largest distribution vehicle for its technology. The partnership enables Ypsomed's customer base to access CamAPS FX's adaptive closed-loop algorithm.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-03
Description

Dexcom G7 CGM system integration with myLoop/CamAPS FX launched in Switzerland in June 2026, with rollout to 17 additional countries (Australia, Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, New Zealand, Norway, Poland, Spain, Sweden, United Kingdom) planned by end of June 2026. The integration brings Dexcom G7's fast warm-up time and accuracy to the CamAPS FX ecosystem, expanding sensor choice for users.

3Abbott (FreeStyle Libre)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-01
Description

Abbott's FreeStyle Libre 2 and FreeStyle Libre 3 integrated CGM systems received FDA clearance for integration into AID systems in the US, enabling connection with CamAPS FX. Abbott also partnered with Ypsomed and CamDiab to integrate FreeStyle Libre 3 with their systems in Germany, with additional European countries to follow. Abbott acquired Bigfoot Biomedical in 2023 and integrated its connected insulin pen caps into the FreeStyle Libre ecosystem, expanding its diabetes management partnerships.

abbott.com
4Cambridge Diabetes Education Programme (CDEP)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CamDiab provides free certified online training for healthcare professionals through CDEP, the Cambridge Diabetes Education Programme. This training programme is the primary mechanism for driving clinical adoption and prescriber education for CamAPS FX.

camdiab.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The CamAPS algorithm was developed at the University of Cambridge over more than 15 years of research (2006–present). The company was spun out from Cambridge University, and founder Professor Roman Hovorka remains affiliated with the university. The Cambridge research programme includes trials in children, adolescents, adults, pregnant women, and elderly patients, providing the clinical evidence base for CamAPS FX.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeEmerging player
Description

Diabeloop is a European direct competitor developing hybrid closed-loop algorithms (DBLG1, DBLG2) integrated with pumps and CGMs, comparable in approach to CamAPS FX and active in EU markets.

TypeEmerging player
Description

Beta Bionics developed the iLet bionic pancreas with an algorithm that, like CamAPS Liberty, eliminates the need for carb counting. Direct competitor in the fully closed-loop / bihormonal AID space.

TypeDirect peer
Description

Insulet's Omnipod 5 is a tubeless patch pump with a hybrid closed-loop algorithm (SmartAdjust) directly competing with CamAPS FX-enabled systems. Targeted to similar type 1 diabetes populations with smartphone-app control.

TypeDirect peer
Description

Tandem's Control-IQ hybrid closed-loop algorithm on the t:slim X2 pump is a direct competitor to CamAPS FX in adaptive AID for type 1 diabetes. Both target smartphone-connected, multi-CGM-compatible closed-loop insulin delivery.

TypeOthers
Description

Dexcom provides CGM sensor integrations with CamAPS FX (partner) but is also building broader AID ecosystem positioning. Closely tied to CamDiab via Dexcom G7 launch in 17 countries.

6Abbott (FreeStyle Libre / AID ecosystem)
TypeOthers
Description

Abbott's FreeStyle Libre 3/3+ iCGM is a compatible sensor for CamAPS FX; Abbott is an integration partner. Comparable as a diabetes technology ecosystem player pursuing integrated AID via partnerships and Bigfoot Biomedical acquisition.

TypeOthers
Description

Ypsomed is CamDiab's primary channel partner, embedding CamAPS FX into its myLoop AID system via the YpsoPump. Not a competitor but a strategic distribution enabler comparable as a diabetes device company.

TypeBroad incumbent
Description

Medtronic is the incumbent leader in automated insulin delivery via its 780G hybrid closed-loop system bundling pump, CGM, and algorithm. Competes with CamAPS FX in the hybrid/closed-loop AID category for type 1 diabetes.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration9 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CamDiab

Automated Insulin Delivery Software (Diabetes Management)camdiab.com

CamDiab develops CamAPS FX, an adaptive hybrid closed-loop mobile app that automates insulin delivery for people with type 1 diabetes by linking continuous glucose monitors and insulin pumps to its proprietary Cambridge algorithm, with EU MDR-approved CamAPS Liberty extending it to fully closed-loop operation.

What CamDiab does

CamDiab Ltd is a Cambridge- and London-based private digital health company that develops and commercialises the CamAPS FX mobile application, an adaptive hybrid closed-loop insulin delivery system for people aged one year and older with type 1 diabetes. The app connects to compatible continuous glucose monitors (Dexcom G6/G7, Abbott FreeStyle Libre 3/3 Plus) and insulin pumps (YpsoPump, DANA Diabecare RS, DANA-i), running the proprietary Cambridge self-learning algorithm — refined over 15+ years of research at the University of Cambridge and validated in randomised trials published in The Lancet, NEJM, and Diabetes Care — to compute and direct insulin doses every 8 to 12 minutes. In January 2026 the company received EU MDR notified body approval for CamAPS Liberty, the world's first commercially available fully closed-loop feature, which removes the need for carbohydrate counting and pre-meal bolusing.

CamDiab generates revenue through two complementary streams: direct app subscriptions sold via its website and the Google Play/Apple App Store (£80 per month, £450 per six months, or £840 per year, with a 30-day free trial), and B2B algorithm licensing and OEM integration with device partners — most prominently Ypsomed's mylife Diabetes Care, where CamAPS FX is embedded as the algorithm engine inside the myLoop AID system. Abbott and Dexcom partnerships extend CGM compatibility, while Cambridge Diabetes Education Programme (CDEP) certification provides free healthcare professional training as an indirect adoption driver. The company holds regulatory approvals across six major markets (UK, EU, USA, Canada, Australia, New Zealand), operates with 1-10 employees in a founder-led structure under Professor Roman Hovorka, and pursues growth through market-by-market geographic expansion, additional device integrations, and the staged rollout of its fully closed-loop CamAPS Liberty feature.

CamDiab firmographics

Firmographics
Name
CamDiab
Legal name
CamDiab Ltd
Website
https://camdiab.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
CamDiab develops CamAPS FX, an adaptive hybrid closed-loop mobile app that automates insulin delivery for people with type 1 diabetes by linking continuous glucose monitors and insulin pumps to its proprietary Cambridge algorithm, with EU MDR-approved CamAPS Liberty extending it to fully closed-loop operation.
Ownership category
akta.pro rank

CamDiab industry classification

Industry
Product category
Automated Insulin Delivery Software (Diabetes Management)
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Software Publishers (513210)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAHAF
Automated Insulin Delivery (AID) / Closed-Loop Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)

Keywords

  • Automated insulin delivery
  • Diabetes management software
  • Hybrid closed-loop app
  • Continuous glucose monitoring
  • Type 1 diabetes technology

Where CamDiab is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

CamDiab business model

Business model
GTM type
B2C
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. CamAPS FX App Subscription: CamAPS FX is sold as a downloadable mobile app with monthly, 6-monthly, and annual subscription options. Subscriptions are purchased through the company website, Google Play, and Apple App Store, or via voucher codes. The app requires users to complete certified online training before activation. Pricing is publicly listed at £80/month, £450 for 6 months, or £840/year (plus VAT unless exempt). A 30-day free trial is available using discount code CamAPS30. Usage fees are payable in advance and non-refundable except in specific circumstances outlined in the T&Cs.
  2. Healthcare Professional Training Services: CamDiab provides FREE certified online HCP training via the Cambridge Diabetes Education Programme (CDEP). While the training itself is free, it serves as a gatekeeper and adoption driver for clinical prescription and recommendation of CamAPS FX, indirectly driving subscription revenue.
  3. Algorithm Licensing / OEM Integration: CamDiab's CamAPS algorithm is embedded within Ypsomed's mylife Loop/AID ecosystem and integrated with Abbott's FreeStyle Libre 3 and Dexcom G7. These partnerships suggest a licensing or OEM arrangement where CamDiab's technology is incorporated into partners' AID systems, generating revenue from technology integration fees or per-unit royalties.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyMonthly subscription — £80 per month
SubscriptionMulti-year contract6-month subscription — £450 (£30 saving)
SubscriptionAnnualAnnual subscription — £840 (£120 saving)

Go-to-market motion3 records

Distribution channels6 records

Marketing channels9 records

CamDiab product offering

Product offering

Core offering

CamDiab develops and commercialises the CamAPS FX mobile application, an adaptive hybrid closed-loop system that automatically adjusts insulin delivery from a compatible insulin pump based on continuous glucose monitor (CGM) readings every 8–12 minutes for people with type 1 diabetes aged one year and over. The app is sold on a subscription basis directly to consumers via app stores and the company website, and is also licensed as the algorithm engine within partner AID ecosystems such as Ypsomed's myLoop system, with Abbott FreeStyle Libre 3 and Dexcom G7 sensor integrations.

Product overview

CamDiab offers a mobile health platform centered on its CamAPS FX app, an advanced adaptive hybrid closed-loop system for automated insulin delivery in type 1 diabetes. The core CamAPS FX app connects to compatible continuous glucose monitors (Dexcom G6/G7, FreeStyle Libre 3/3 Plus) and insulin pumps (YpsoPump, DANA Diabecare RS, DANA-i) to autonomously compute and direct insulin delivery. The company has expanded its portfolio with CamAPS Liberty, the world's first commercially available fully closed-loop feature, which removes the need for carb counting and meal bolusing. CamAPS HX represents an extension for non-type 1 diabetes populations. The platform is complemented by data sharing integrations with mylife Cloud and Glooko, and the Companion feature enabling remote caregiver monitoring.

Differentiator

Problem solved

Functional benefit

Brands

  • CamAPS FX: Advanced adaptive hybrid closed-loop mobile app for people with type 1 diabetes that automatically adjusts insulin delivery based on sensor glucose readings.
  • CamAPS Liberty
  • mylife CamAPS FX

Products and services

  • CamAPS FX Advanced adaptive hybrid closed-loop mobile application that automatically adjusts insulin delivery on a compatible insulin pump based on continuous glucose monitor (CGM) sensor readings every 8–12 minutes. Designed for people with type 1 diabetes aged one year and older who use a compatible CGM and insulin pump. Sold via subscription through app stores and the CamDiab website, and licensed into partner AID systems.
  • CamAPS Liberty Fully closed-loop feature within the CamAPS FX app that, when activated, removes the need for users to count carbohydrates or deliver pre-meal insulin boluses. The algorithm autonomously handles meal-related insulin dosing while maintaining established safety boundaries, targeting people with type 1 diabetes aged 13 and over.
  • CamAPS HX App offering fully closed-loop insulin delivery for non-type 1 diabetes populations, extending the CamAPS algorithm beyond its type 1 diabetes indication.

Quantifiable outcome

  • Significant increase in time in range, reduction in HbA1c, reduction in time spent in hypoglycaemia and hyperglycaemia, and improved well-being (randomised clinical trials)
  • +4 more outcomes

Companies that use CamDiab

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

CamDiab technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration9 records

AI capability3 records

Feature6 records

CamDiab partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Ypsomed / mylife Diabetes CarecoreTechnology or Integration · 3 June 2026CamAPS FX is embedded as the algorithm engine within Ypsomed's mylife Loop/AID ecosystem, integrating the YpsoPump insulin pump with CamAPS FX and compatible sensors. Ypsomed distributes the combined system globally, with the Dexcom G7 integration (June 2026) jointly announced by all three companies. This is CamDiab's primary channel partnership and the largest distribution vehicle for its technology. The partnership enables Ypsomed's customer base to access CamAPS FX's adaptive closed-loop algorithm.
  • DexcomcoreTechnology or Integration · 3 June 2026Dexcom G7 CGM system integration with myLoop/CamAPS FX launched in Switzerland in June 2026, with rollout to 17 additional countries (Australia, Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, New Zealand, Norway, Poland, Spain, Sweden, United Kingdom) planned by end of June 2026. The integration brings Dexcom G7's fast warm-up time and accuracy to the CamAPS FX ecosystem, expanding sensor choice for users.
  • Abbott (FreeStyle Libre)coreTechnology or Integration · 1 November 2025Abbott's FreeStyle Libre 2 and FreeStyle Libre 3 integrated CGM systems received FDA clearance for integration into AID systems in the US, enabling connection with CamAPS FX. Abbott also partnered with Ypsomed and CamDiab to integrate FreeStyle Libre 3 with their systems in Germany, with additional European countries to follow. Abbott acquired Bigfoot Biomedical in 2023 and integrated its connected insulin pen caps into the FreeStyle Libre ecosystem, expanding its diabetes management partnerships.
  • Cambridge Diabetes Education Programme (CDEP)coreStrategic or Co-development PartnerCamDiab provides free certified online training for healthcare professionals through CDEP, the Cambridge Diabetes Education Programme. This training programme is the primary mechanism for driving clinical adoption and prescriber education for CamAPS FX.
  • University of CambridgecoreStrategic or Co-development PartnerThe CamAPS algorithm was developed at the University of Cambridge over more than 15 years of research (2006–present). The company was spun out from Cambridge University, and founder Professor Roman Hovorka remains affiliated with the university. The Cambridge research programme includes trials in children, adolescents, adults, pregnant women, and elderly patients, providing the clinical evidence base for CamAPS FX.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

CamDiab competitors and assessment

Company assessment

Emerging players

  • Diabeloop: Diabeloop is a European direct competitor developing hybrid closed-loop algorithms (DBLG1, DBLG2) integrated with pumps and CGMs, comparable in approach to CamAPS FX and active in EU markets.
  • Beta Bionics (iLet bionic pancreas): Beta Bionics developed the iLet bionic pancreas with an algorithm that, like CamAPS Liberty, eliminates the need for carb counting. Direct competitor in the fully closed-loop / bihormonal AID space.

Direct peers

  • Insulet (Omnipod 5): Insulet's Omnipod 5 is a tubeless patch pump with a hybrid closed-loop algorithm (SmartAdjust) directly competing with CamAPS FX-enabled systems. Targeted to similar type 1 diabetes populations with smartphone-app control.
  • Tandem Diabetes Care (t:slim X2 / Control-IQ): Tandem's Control-IQ hybrid closed-loop algorithm on the t:slim X2 pump is a direct competitor to CamAPS FX in adaptive AID for type 1 diabetes. Both target smartphone-connected, multi-CGM-compatible closed-loop insulin delivery.

Others

  • Dexcom (G7 CGM + algorithms): Dexcom provides CGM sensor integrations with CamAPS FX (partner) but is also building broader AID ecosystem positioning. Closely tied to CamDiab via Dexcom G7 launch in 17 countries.
  • Abbott (FreeStyle Libre / AID ecosystem): Abbott's FreeStyle Libre 3/3+ iCGM is a compatible sensor for CamAPS FX; Abbott is an integration partner. Comparable as a diabetes technology ecosystem player pursuing integrated AID via partnerships and Bigfoot Biomedical acquisition.
  • Ypsomed (myLoop / mylife Diabetes Care): Ypsomed is CamDiab's primary channel partner, embedding CamAPS FX into its myLoop AID system via the YpsoPump. Not a competitor but a strategic distribution enabler comparable as a diabetes device company.

Broad incumbents

  • Medtronic (MiniMed 780G): Medtronic is the incumbent leader in automated insulin delivery via its 780G hybrid closed-loop system bundling pump, CGM, and algorithm. Competes with CamAPS FX in the hybrid/closed-loop AID category for type 1 diabetes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

CamDiab social profiles

Digital presence

CamDiab compliance and trust

Trust signal

Compliance6 records

CamDiab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CamDiab leadership team

Management profile

Number of profiles

Profiles1 record

CamDiab funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CamDiab M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CamDiab

What does CamDiab do?

CamDiab develops and commercialises the CamAPS FX mobile application, an adaptive hybrid closed-loop system that automatically adjusts insulin delivery from a compatible insulin pump based on continuous glucose monitor (CGM) readings every 8–12 minutes for people with type 1 diabetes aged one year and over. The app is sold on a subscription basis directly to consumers via app stores and the company website, and is also licensed as the algorithm engine within partner AID ecosystems such as Ypsomed's myLoop system, with Abbott FreeStyle Libre 3 and Dexcom G7 sensor integrations.

Is CamDiab a public or private company?

CamDiab is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was CamDiab founded?

CamDiab was founded in 2019. It employs 11 to 50 people.

Where is CamDiab based?

CamDiab is headquartered in Cambridge, United Kingdom, in the Europe region.

How does CamDiab make money?

Three revenue lines are on record. CamAPS FX App Subscription is the primary driver. The others are healthcare Professional Training Services and algorithm Licensing / OEM Integration.

Who are CamDiab's main competitors?

Emerging players on record are Diabeloop and Beta Bionics (iLet bionic pancreas). Direct peers are Insulet (Omnipod 5) and Tandem Diabetes Care (t:slim X2 / Control-IQ). Others are Dexcom (G7 CGM + algorithms), Abbott (FreeStyle Libre / AID ecosystem) and Ypsomed (myLoop / mylife Diabetes Care). Medtronic (MiniMed 780G) is listed as a broad incumbent.

Does CamDiab have an API?

No public API is recorded for CamDiab.

What industry is CamDiab in?

CamDiab's product category is Automated Insulin Delivery Software (Diabetes Management). Its primary akta.pro industry code is HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems, with a secondary code of HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
IDTechExDiabetes on Autopilot: The Arrival of Fully Closed LoopCamDiab launched CamAPS Liberty, the first fully closed-loop automated insulin delivery system, requiring no carbohydrate counting or manual boluses. The system received EU MDR approval in January 2026, with a controlled pilot in early 2026 and staged commercial rollout. IDTechEx estimates such systems will hit the market meaningfully within three to five years.DrugdeliverybusinessThe biggest diabetes tech news out of ATTD 2026At ATTD 2026 in Vienna, multiple diabetes technology companies presented product launches, clinical data, and enhancements in automated insulin delivery and continuous glucose monitoring (CGM) technologies. Key developments include CamDiab introducing the world's first fully closed-loop feature (CamAPS Liberty), Medtronic receiving CE mark for its MiniMed 780G pump paired with Abbott's Instinct sensor, and several companies presenting positive clinical outcomes for type 2 diabetes applications. Multiple companies are advancing toward fully closed-loop systems for type 2 populations, with Insulet targeting a 2028 launch for its Omnipod system in this indication.DrugdeliverybusinessCamDiab launches fully closed-loop automated insulin delivery techCamDiab announced the launch of CamAPS Liberty, a fully closed-loop automated insulin delivery feature for its CamAPS FX app, at the ATTD Congress 2026 in Barcelona. The technology automates insulin delivery by eliminating the need for users to count carbohydrates or deliver meal boluses. CamDiab plans to make this feature available to all users pending market-specific regulatory approvals.AbbottComing to the AID of People with DiabetesAbbott announced that its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitors (iCGMs) have received FDA clearance for integration into Automated Insulin Delivery (AID) systems in the United States, enabling the technology to connect with insulin pumps to automate insulin delivery based on real-time glucose data. The company also recently partnered with Ypsomed and CamDiab to integrate its FreeStyle Libre 3 technology with their systems in Germany, with additional European countries to follow. The article describes how AID systems combine iCGM technology, insulin pumps, and algorithms to reduce the manual burden of diabetes management by automatically adjusting insulin delivery.AbbottThe Partnerships Changing How You Manage DiabetesAbbott is forming strategic partnerships to integrate its FreeStyle Libre glucose monitoring systems with multiple insulin delivery systems from companies including Bigfoot Biomedical, Insulet, Novo Nordisk, Sanofi, Tandem, and Ypsomed/CamDiab. These collaborations aim to create seamless, personalized diabetes care by combining continuous glucose monitoring data with insulin dosing tools, addressing the needs of approximately 63 million people worldwide who require insulin. Several of the integrated products are already available in markets such as the United States, Canada, and Europe, while others remain under development.PR NewswireFDA Roundup: May 24, 2024The FDA announced that Medline Industries, LP, a firm marketing and distributing plastic syringes made in China within the U.S., initiated a voluntary recall to stop using affected unauthorized plastic syringes, and Jiangsu Shenli Medical Production Co. Ltd, the China-based manufacturer, also initiated a recall of its unauthorized syringes. The FDA cleared for marketing CamAPS FX by CamDiab Ltd, a prescription-only mobile app for automated insulin dosing for Type 1 diabetes patients two years and older, including pregnant patients, representing the first such device approved for this population. The agency also launched its 'Prescribe with Confidence' campaign to raise awareness about opioid use disorder treatment and approved Safe-Guard for treating gastrointestinal parasites in wild quail.MeditechinsightsDiabetes Devices Market Research ReportThis article presents a market research report on the global diabetes devices sector, projecting a 6% growth rate by 2031 driven by rising diabetes prevalence and technological advancements in continuous glucose monitoring. It highlights specific corporate activities, including partnerships between Abbott, CamDiab, and Ypsomed for automated insulin delivery systems, and regulatory clearances granted to Insulet Corporation's Omnipod 5 system. The report also analyzes economic headwinds, noting that recession fears have led some patients to reduce spending on newer devices.News Release ArchiveAbbott, CamDiab and Ypsomed Unveil New Automated Insulin Delivery Partnership for People with DiabetesAbbott, CamDiab, and Ypsomed announced a partnership to develop an automated insulin delivery system combining FreeStyle Libre 3, CamAPS FX, and YpsoPump. The system targets European markets, with development completion by end of 2022 and commercial availability thereafter.Medical Device and Diagnostic industryDiabetes Partnership Trifecta Is a Win for European PatientsAbbott, CamDiab, and Ypsomed have formed a partnership to develop an integrated automated insulin delivery system that connects Abbott's FreeStyle Libre 3 sensor with CamDiab's CamAPS FX app and Ypsomed's mylife YpsoPump. The collaboration aims to create a smart wearable solution for European patients that automatically adjusts insulin dosing based on real-time glucose data, with development targeted for completion by the end of the year.